Gilead Sciences, Inc.

Foster City, CA 94404

Market Performance

NASDAQ: GILD
Market Cap $97.9 Billion
52 Week High $86.27
52 Week Low $63.76

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.1MM
First Award Date 09/11/00
Most Recent Award Date 01/02/04

Key Personnel

Last Name Name Awards Contact
Rindt Hansjorg Rindt 1
Pagratis Nikos C Pagratis 3
Gorczynski Richard J Gorczynski 1

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/02/04 - 09/30/04

DESCRIPTION (provided by applicant): Chronic (or congestive) heart failure is a clinical syndrome that affects approximately 700,000 individuals yearly in the United States with an annual estimated health care cost of $ 10-40 billion. Heart failure is a progressive disease that ultimately leads to premature death. The expanding number of those a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 08/31/04

DESCRIPTION (provided by applicant): Heart failure (HF) affects 700,000 individuals yearly in the United States, accounting for $10-40 billion annual cost. Although the last ten years have seen dramatic improvements in therapeutic approaches to HF, the expanding number of patients with chronic HF and its persistently poor prognosis make it clear...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/23/02 - 08/31/03

DESCRIPTION (provided by applicant): Heart failure (HF) affects 700,000 individuals yearly in the United States, accounting for $10-40 billion annual cost. Although the last ten years have seen dramatic improvements in therapeutic approaches to HF, the expanding number of patients with chronic HF and its persistently poor prognosis make it clear...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/00 - 03/31/01

Myogen proposes to develop and optimize a long-term culture system for adult human cardiac myocytes. Failing explanted and non-failing organ donor human hearts will be used to isolate cardiac myocytes for culture. The cultured cells will be characterized to validate their phenotype. The developed culture systems will ultimately be used to estab...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/11/00 - 09/10/01

Heart failure (HF) affects 700,000 individuals yearly in the United States, accounting for $10-40 billion annual cost. Although the last ten years have seen dramatic improvements in therapeutic approaches to HF, the expanding number of patients with chronic HF and its persistently poor prognosis make it clear that additional novel treatment appr...